ConductScience.org, home

Paper32059151

MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.

Han X and 9 others. Theriogenology, 2020. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos. Papers, record 32059151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32059151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
PubMed
Journal
Theriogenology
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.37
iCite
Revised in PubMed
2021-12-04
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Han XXuejie
2Xiang JJinzhu
3Li CChen
4Wang JJing
5Wang CChen
6Zhang YYuanyuan
7Li ZZihong
8Lu ZZhenyu
9Yue YYongli
10Li XXueling

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CattleMajor topic
Fertilization in VitroMajor topic
Glycogen Synthase Kinase 3Major topic
Histone-Lysine N-MethyltransferaseMajor topic
Mitogen-Activated Protein Kinase KinasesMajor topic
Myeloid-Lymphoid Leukemia ProteinMajor topic
Animals
Embryo Culture Techniques
Female
Gene Expression Regulation, Developmental
Kruppel-Like Factor 4

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
41379212
Silencing KMT2A with siRNA induces apoptosis and cell cycle arrest in high-grade serous ovarian carcinoma cells by modulating GOF p53-dependent pathways, highlighting its potential as a therapeutic target.
Med Oncol2025https://conductscience.org/library/papers/41379212PubMed
38202281WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.J Clin Med2024https://conductscience.org/library/papers/38202281PubMed
37708089A novel TOX3-WDR5-ABCG2 signaling axis regulates the progression of colorectal cancer by accelerating stem-like traits and chemoresistance.PLoS Biol2023https://conductscience.org/library/papers/37708089PubMed
37569280Mixed-Lineage Leukemia 1 Inhibition Enhances the Differentiation Potential of Bovine Embryonic Stem Cells by Increasing H3K4 Mono-Methylation at Active Promoters.Int J Mol Sci2023https://conductscience.org/library/papers/37569280PubMed
37031197KLF4 transcription factor in tumorigenesis.Cell Death Discov2023https://conductscience.org/library/papers/37031197PubMed
36847888The adaptation of bovine embryonic stem cells to the changes of feeder layers.In Vitro Cell Dev Biol Anim2023https://conductscience.org/library/papers/36847888PubMed
35454256Pluripotent Core in Bovine Embryos: A Review.Animals (Basel)2022https://conductscience.org/library/papers/35454256PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32059151

GET https://conductscience.org/api/papers/v1/32059151/authors